APPLICATION
NDA204914
TYPE
NDA
LATEST ACTION
2015-05-14
ROUTE
ORAL SUSPENSION
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
LAMIVUDINE; ZIDOVUDINENone (Tentative Approval)
LAMIVUDINE 30MG, ZIDOVUDINE 60MG · TABLET · ORAL SUSPENSION
Approval history
2015-05-14Manufacturing (CMC) · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.